Investors & Media

2009 News and Events

Date Title   12/22/09 / CORRECTION -- The Medicines Company Acquires ApoA-I Milano From Pfizer PARSIPPANY, NJ and NEW YORK, NY, Dec 22, 2009 (MARKETWIRE via COMTEX) -- In the news release, "The Medicines Company Acquires ApoA-I Milano From Pfizer," issued earlier today by The Medicines Company (NASDAQ: MDCO), we are advised by the company that the Domestic Dial In number for the Wednesday, December 23 conference call should be 866-825-1709 rather than 866-285-1709 as originally issued. Complete corrected text follows. The Medicines Company Acquires ApoA-I Milano From Pfizer Produ...  12/16/09 The Medicines Company Issues a Nationwide Recall for Certain Lots of Cleviprex(R) That May Contain Particulate Matter PARSIPPANY, N.J, Dec 16, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that it is voluntarily recalling eleven (11) lots of Cleviprex(R) (clevidipine butyrate) injectable emulsion due to the potential presence of visible particulate matter which has been observed in some vials during a routine annual inspection. The affected Cleviprex lots are 61-978-DW, 61-979-DW, and 61-980-DW, Exp. 01/2010; 68-404-DJ, 68-405-DJ, and 68-406-DJ, Exp. 08/2010; 69-830-DJ, 63...  12/15/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Dec 15, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to one new hire. The inducement stock options cover 15,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10-year term and vest over four years as follows: 25 percent of...  12/01/09 The Medicines Company Receives European Approval for Angiox(R) (Bivalirudin) for Use in Heart Attack Patients Undergoing Emergency Heart Procedures —European Commission Decision based on landmark HORIZONS-AMI trial data— PARSIPPANY, N J--(BUSINESS WIRE)--Dec. 1, 2009-- The Medicines Company (NASDAQ: MDCO) announced today that it has received European approval for the use of Angiox® (bivalirudin) as an anticoagulant in patients with heart attacks (so-called ST-segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous c...  11/30/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Nov 30, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to two new hires. The inducement stock options cover 1,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10-year term and vest over four years as follows: 25 percen...  11/15/09 The Medicines Company's Full Analysis of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patient Outcomes Following PCI Data From Two International Trials With Nearly 14,000 Patients Presented at American Heart Association Scientific Sessions and Published in Two Papers in the New England Journal of Medicine FOR U.S. AUDIENCES ONLYPARSIPPANY, NJ, Nov 15, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced the data from 13,941 patients treated in the discontinued CHAMPION Phase III program of cangrelor. While cangrelor did not show superiority to 600 mg clopidogrel given orally...  11/12/09 Cleviprex Results Reported From Study in Patients With Intracerebral Hemorrhage ACCELERATE Data Presented at the Annual Meeting of the Neurocritical Care SocietyPARSIPPANY, NJ, Nov 12, 2009 (MARKETWIRE via COMTEX) -- First reported interim data from the Evaluation of patients with acute hypertension and intracerebral hemorrhage with intravenous clevidipine treatment (ACCELERATE) trial were presented today at the Neurocritical Care Society (NCS) 2009 Annual Meeting, showing that Cleviprex (clevidipine butyrate) effectively and safely reduces blood pressure in patients w...  10/28/09 The Medicines Company Reports Third Quarter 2009 Financial Results Total Sales in Third Quarter Up 12%, Year to Date Up 19%, Despite Economic Pressures on U.S. Hospitals and Reduced PCI VolumePARSIPPANY, NJ, Oct 28, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced its financial results for the third quarter of 2009. Financial highlights for the third quarter of 2009: -- Net revenue increased by 12% to $98.8 million for the third quarter of 2009 from $88.1 million for the third quarter of 2008. -- Angiomax U...  10/23/09 The Medicines Company Announces Positive CHMP Opinion for Angiox(R) (Bivalirudin) for Use in Heart Attack Patients Undergoing Emergency Heart Procedures --Approval based on landmark HORIZONS-AMI trial data--PARSIPPANY, N.J., Oct 23, 2009 (BUSINESS WIRE) -- The Medicines Company (NASDAQ:MDCO) announced today that the Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion applicable to all Member States of the European Union/European Economic Area that will extend the use of Angiox (bivalirudin) to include patients with heart attacks (so-called ST segment elevation myocardial in...  10/15/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Oct 15, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to five new hires due to additional hiring in connection with its global expansion. The inducement stock options cover 21,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options...  10/08/09 The Medicines Company Files Patent Infringement Lawsuits PARSIPPANY, NJ, Oct 08, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced that it has filed lawsuits against Teva Parenteral Medicines, Inc., Pliva Hrvatska d.o.o. and APP Pharmaceuticals, LLC, and related entities in the United States District Court for the District of Delaware alleging patent infringement based on Abbreviated New Drug Applications seeking U.S. Food and Drug Administration approval to market and sell generic versions of The Medicines Com...  10/08/09 The Medicines Company Announces Second New Patent Issuance for Angiomax(R) PARSIPPANY, NJ, Oct 08, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced that the United States Patent and Trademark Office (PTO) issued a new U.S. patent No. 7,598,343 ('343 patent). The '343 patent relates to a more consistent and improved Angiomax drug product made by processes described in the patent. The new patent has been listed in the U.S. Food and Drug Administration's publication "Approved Drug Products with Therapeutic Equivalence Evaluation...  10/06/09 The Medicines Company Announces Preliminary Third Quarter 2009 Top Line Results PARSIPPANY, NJ, Oct 06, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced preliminary revenue results for the third quarter of 2009. Based on a preliminary review of third quarter results, the Company expects to report total net revenue in the range of $96 to $98 million for the third quarter of 2009, as compared to the $88.1 million reported for the third quarter of 2008. The Company has scheduled its quarterly conference call for Wednesday, October 28...  10/02/09 The Medicines Company Announces the Resignation of Its Chief Operating Officer PARSIPPANY, NJ, Oct 02, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced the resignation of John P. Kelley as the Company's President and Chief Operating Officer. On September 29, 2009, John P. Kelley resigned as President and Chief Operating Officer and as director of the Company to pursue other interests, effective October 1, 2009. Mr. Kelley will serve as a Special Advisor to the Company's Chief Executive Officer until the earlier of December 31, 20...  09/30/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Sep 30, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to five new hires. The inducement stock options cover 12,800 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10-year term and vest over four years as follows: 25 perc...  09/29/09 The Medicines Company Licenses Innovative New Formulation of Argatroban; Gains Strategic Complement to Angiomax Franchise and Potential Near Term Revenue Opportunity PARSIPPANY, NJ, Sep 29, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced that it has entered into a license agreement with Eagle Pharmaceuticals, Inc. (Eagle) under which The Medicines Company will have rights in the United States and Canada to a ready-to-use formulation of Argatroban, which is currently under review by the U.S. Food and Drug Administration (FDA). "The Medicines Company is pleased to announce our agreement with Eagle," said Clive Meanwe...  09/25/09 Angiomax Reduced Cardiac Mortality by 41%; Reduced Overall Mortality by 25% in Severe Heart Attack Patients Following Angioplasty HORIZONS-AMI Trial Two-Year Results Presented at TCTPARSIPPANY, NJ, Sep 25, 2009 (MARKETWIRE via COMTEX) -- FOR U.S. AUDIENCES ONLY The Medicines Company (NASDAQ: MDCO) today announced the presentation of 2-year clinical results from the landmark HORIZONS-AMI Trial. The trial showed that patients who had suffered the most severe form of heart attack were significantly less likely to suffer cardiac death and had better overall survival if treated with Angiomax(R) (bivalirudin) while underg...  09/16/09 The Medicines Company to Participate in the UBS Global Life Sciences Conference PARSIPPANY, NJ, Sep 16, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) is scheduled to participate in the UBS Global Life Sciences Conference on Wednesday, September 23rd, 2009. John Kelley, President and Chief Operating Officer, will present at 9:00am Eastern Time. A company overview will be provided in the presentation. The session will be webcast with a link available at The Medicines Company's website: http://www.themedicinescompany.com. About The Medicines C...  09/15/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Sep 15, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to four new hires due to additional hiring in connection with its global expansion. The inducement stock options cover 8,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options ...  09/04/09 The Medicines Company Receives Paragraph IV Notifications PARSIPPANY, NJ, Sep 04, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced that it has received Paragraph IV Certification notice letters from Teva Parenteral Medicines, Inc. (TPM) and Pliva Hrvatska, d.o.o. (Pliva) notifying the Company that TPM and Pliva have submitted Abbreviated New Drug Applications (ANDAs) to the U.S. Food and Drug Administration (FDA) for approval to market generic versions of Angiomax. The Certification notice letters relate to U....  09/02/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Sep 02, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to four new hires due to additional hiring in connection with its global expansion. The inducement stock options cover 31,800 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options...  09/02/09 The Medicines Company Announces New Patent Issuance for Angiomax(R) PARSIPPANY, NJ, Sep 02, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced that the United States Patent and Trademark Office (PTO) issued a new U.S. patent No. 7,582,727 ('727 patent). The '727 patent relates to a more consistent and improved Angiomax drug product. The new patent has been submitted to the U.S. Food and Drug Administration (FDA) for listing in the FDA's publication "Approved Drug Products with Therapeutic Equivalence Evaluations," which ...  08/31/09 The Medicines Company Announces New Publication of Data Showing Angiomax(R) Reduces Cardiac Mortality and Improves Overall Survival HORIZONS-AMI Trial One-Year Results Published in The LancetPARSIPPANY, NJ, Aug 31, 2009 (MARKETWIRE via COMTEX) -- FOR U.S. AUDIENCES ONLY The Medicines Company (NASDAQ: MDCO) today announced the publication of one-year results from the landmark HORIZONS-AMI Trial. The trial showed that patients who had suffered the most severe form of heart attack and received angioplasty were significantly less likely to suffer cardiac death and had significantly better overall survival if treated with A...  08/20/09 The Medicines Company Withdraws European Marketing Application for 3-7 Day Daily Dose Oritavancin Therapy PARSIPPANY, NJ, Aug 20, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced the withdrawal of the European marketing authorization application (MAA) for the 200mg 3-7 day daily dose therapy of oritavancin, its investigational antibiotic drug candidate for the treatment of complicated skin and skin structure infections (cSSSI) caused by gram positive pathogens. The MAA was filed in Europe in June 2008, by Targanta Therapeutics Corp. (Targanta). The Medicines...  08/14/09 The Medicines Company Announces Option Grants Under Nasdaq Marketplace Rule 5635 PARSIPPANY, NJ, Aug 14, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to four new hires due to additional hiring in connection with its global expansion. The inducement stock options cover 16,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options...  08/10/09 The Medicines Company Responds to Incorrect News Reports PARSIPPANY, NJ, Aug 10, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that it had responded to inaccurate implications in a column in The New York Times on August 9, 2009 by Frank Rich and a report that aired on Rachel Maddow's news show on MSNBC on August 6, 2009. The column and report both contained statements that incorrectly created the impression that The Medicines Company has engaged lobbyists to oppose pending healthcare reform legislation and...  07/31/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Jul 31, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to one new hire due to additional hiring in connection with its global expansion. The inducement stock options cover 15,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options h...  07/29/09 The Medicines Company Reports Second Quarter 2009 Financial Results Achieves First Quarter of Net Sales in Excess of $100 MillionPARSIPPANY, NJ, Jul 29, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced its financial results for the second quarter of 2009. Highlights for the second quarter of 2009: -- Net revenue increased by 20% to $104.2 million for the second quarter of 2009 from $86.7 million for the second quarter of 2008. -- Angiomax U.S. sales increased by 17% to $98.8 million in the s...  07/23/09 The Medicines Company Appoints T. Scott Johnson as Vice President, New Business Ventures & Chief Medical Advisor PARSIPPANY, NJ, Jul 23, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced that T. Scott Johnson, M.D. joined the Company on a full-time basis as Vice President, New Business Ventures & Chief Medical Advisor, and has resigned as a director. In his new role, Scott will work to evaluate new product acquisition opportunities and provide medical advice on both marketed and development products in the Company's portfolio. "I've known Scott for many years, and ...  07/15/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Jul 15, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to ten new hires due to additional hiring in connection with its global expansion. The inducement stock options covers 10,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options...  07/15/09 The Medicines Company to Announce Second Quarter 2009 Financial Results on Wednesday, July 29, 2009 Conference Call to Be Held at 8:30 a.m. Eastern TimePARSIPPANY, NJ, Jul 15, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, July 29, 2009 at 8:30 a.m. Eastern Time to discuss second quarter 2009 financial results and operational developments. The conference call will be available via phone and webcast. The dial in information is listed below: Domestic Dial In: 800-884-5695 Internatio...  06/30/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Jun 30, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to one new hire due to additional hiring in connection with its global expansion. The inducement stock options covers 1,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options h...  06/19/09 FDA Grants The Medicines Company Pediatric Exclusivity for Angiomax(R) Prospective Study Demonstrates Safety and Predictability of Angiomax in the Pediatric PopulationPARSIPPANY, NJ, Jun 19, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for Angiomax(R) (bivalirudin), based on studies submitted in response to a Written Request by the FDA to investigate the use of Angiomax in pediatric patients aged birth to 16-years old. With this additional ...  06/16/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Jun 16, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to 12 new hires due to additional hiring in connection with its global expansion. The inducement stock options covers 26,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options ...  06/01/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 PARSIPPANY, NJ, Jun 01, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to two executive and non-executive new hires due to additional hiring in connection with its global expansion. The inducement stock options covers 4,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on ...  05/15/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 PARSIPPANY, NJ, May 15, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to three non-executive new hires due to additional hiring in connection with its global expansion. The inducement stock options covers 3,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant da...  05/15/09 The Medicines Company to Participate in the Deutsche Bank Health Care Conference PARSIPPANY, NJ, May 15, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) is scheduled to participate in the Deutsche Bank Health Care Conference on Monday, May 18th, 2009. Clive Meanwell, Chairman and Chief Executive Officer, will present at 10am Eastern Time. A company overview and outlook will be provided in the presentation. The session will be webcast with a link available at The Medicines Company's website: http://www.themedicinescompany.com. About The Medicin...  05/13/09 The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor Interim Analyses Indicate CHAMPION Program Will Not Meet Efficacy Endpoints Company to Continue and Accelerate Phase 2/3 Studies of Cangrelor in Settings Where Oral Drugs Cannot Be Used or Short Half-Life Is DesirablePARSIPPANY, NJ, May 13, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced that it is discontinuing its Phase 3 CHAMPION clinical trial program of cangrelor in patients undergoing percutaneous coronary intervention (PCI). The program's independe...  04/30/09 The Medicines Company Announces Option Grants Under Nasdaq Marketplace Rule 4350 PARSIPPANY, NJ, Apr 30, 2009 (MARKET WIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to one non-executive new hire due in part to additional hiring in connection with its global expansion. The inducement stock options covers 3,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the gr...  04/29/09 The Medicines Company Reports First Quarter 2009 Financial Results Operations Continue to Enable Aggressive Investment in New Products and Global CapabilitiesPARSIPPANY, NJ, Apr 29, 2009 (MARKET WIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced its financial results for the first quarter of 2009. Financial highlights for the first quarter of 2009: -- Net revenue increased by 25% to $99.2 million for the first quarter of 2009 from $79.4 million for the first quarter of 2008. -- Including one-time transaction costs of $4.0 ...  04/15/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 PARSIPPANY, NJ, Apr 15, 2009 (MARKET WIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to two executive and non-executive new hires due to additional hiring primarily in connection with its expansion in both Europe and the U.S. The inducement stock options cover an aggregate of 6,000 shares of common stock and are classified as non-qualified stock options with an ex...  04/15/09 The Medicines Company to Announce First Quarter 2009 Financial Results on Wednesday, April 29, 2009 Conference Call to Be Held at 8:30 a.m. Eastern TimePARSIPPANY, NJ, Apr 15, 2009 (MARKET WIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, April 29, 2009 at 8:30 a.m. Eastern Time to discuss first quarter 2009 financial results and operational developments. The conference call will be available via phone and webcast. The dial in information is listed below: Domestic Dial In: 800-706-7745 International...  04/02/09 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 PARSIPPANY, NJ, Apr 02, 2009 (MARKET WIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to twenty-two executive and non-executive new hires due in part to additional hiring in connection with its acquisition of Targanta Therapeutics Corporation. The inducement stock options cover an aggregate of 163,000 shares of common stock and are classified as non-qualified stock ...  03/26/09 The Medicines Company EU Filing Accepted for Cleviprex(R) for the Treatment of Acute Hypertension PARSIPPANY, NJ, Mar 26, 2009 (MARKET WIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced that the Marketing Authorization Application (MAA) for Cleviprex has been accepted for review in the European Union for the reduction of blood pressure when rapid and predictable control is desired. The MAA for Cleviprex was submitted via the Decentralized Procedure (DCP), with the United Kingdom acting as the Reference Member State. Concerned Member States participating in the rev...  02/26/09 The Medicines Company Completes Acquisition of Targanta Therapeutics Corporation PARSIPPANY, NJ, Feb 26, 2009 (MARKET WIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that it has completed its acquisition of Targanta Therapeutics Corporation through a short-form merger of Boxford Subsidiary Corporation (Boxford), a direct wholly owned subsidiary of The Medicines Company, into Targanta. With the consummation of the merger, Targanta has become a wholly owned subsidiary of The Medicines Company. "This completes another step in our strategy to buil...  02/25/09 The Medicines Company Announces Completion of Tender Offer for Shares of Targanta Therapeutics PARSIPPANY, NJ, Feb 25, 2009 (MARKET WIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today the completion of the tender offer made through Boxford Subsidiary Corporation (Boxford), The Medicines Company's direct wholly owned subsidiary, for all of the outstanding shares of Targanta Therapeutics Corporation (Targanta) common stock. The offering period expired at midnight, New York City time, at the end of Tuesday, February 24, 2009. According to the depositary for the o...  02/18/09 The Medicines Company Reports Full Year and Fourth Quarter 2008 Financial Results PARSIPPANY, NJ, Feb 18, 2009 (MARKET WIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced its financial results for the full year and fourth quarter of 2008. Financial highlights for the full year of 2008: -- Net revenue increased by 35% to $348.2 million for 2008 from $257.5 million for 2007. - Angiomax(R) (bivalirudin) U.S. net revenue increased by 31% to $334.2 million for 2008 from $255.0 million for 2007. - Angiomax/Angiox ex-U.S. net ...  02/04/09 The Medicines Company to Announce Fourth Quarter and Full Year 2008 Financial Results on Wednesday, February 18, 2009 Conference Call to Be Held at 8:30 a.m. Eastern TimePARSIPPANY, NJ, Feb 04, 2009 (MARKET WIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, February 18, 2009 at 8:30 a.m. Eastern Time to discuss fourth quarter and full year 2008 financial results, operational developments, guidance and outlook for 2009. The conference call will be available via phone and webcast. The dial in information is listed below: Domestic Dial In:...  01/27/09 The Medicines Company Commences Tender Offer for All Outstanding Shares of Targanta Therapeutics PARSIPPANY, NJ, Jan 27, 2009 (MARKET WIRE via COMTEX) -- Boxford Subsidiary Corporation, a wholly owned subsidiary of The Medicines Company (NASDAQ: MDCO), commenced a tender offer today to acquire all outstanding shares of common stock of Targanta Therapeutics Corporation (NASDAQ: TARG) for consideration of (1) $2.00 per share, net to the seller in cash, plus (2) the contractual right to receive up to an additional $4.55 per share in contingent cash payments if specified regulatory and co...  01/12/09 The Medicines Company to Acquire Targanta Therapeutics Acquisition Would Expand Global Critical Care Pipeline With Phase 3 Hospital Antibiotic Oritavancin for Serious InfectionsPARSIPPANY, NJ, Jan 12, 2009 (MARKET WIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced that it has entered into a merger agreement with Targanta Therapeutics Corporation (NASDAQ: TARG) under which The Medicines Company has agreed to commence a tender offer to acquire 100 percent of Targanta's outstanding shares. "The Medicines Company is pleased to...  01/06/09 The Medicines Company to Participate in the 27th Annual JP Morgan Healthcare Conference PARSIPPANY, NJ, Jan 06, 2009 (MARKET WIRE via COMTEX News Network) -- The Medicines Company (NASDAQ: MDCO) is scheduled to participate in the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13th, at 9am Pacific Time, 12:00pm Eastern Time. A company overview and outlook will be provided in the presentation. The session will be webcast with a link available at The Medicines Company's website: http://www.themedicinescompany.com. MDCO-G About The Medicines Company The ...